What is the impact of Inflation Reduction Act negotiated prices for non-insulin diabetes drugs on Louisiana Medicare costs? A forecasting model analysis
Pharmacoeconomics and Policy · 2025
DOI: 10.1016/j.pharp.2025.09.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoeconomics and Policy, 2025. Verfasst von Debra Winberg und 4 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State of Louisiana Board of Regents, Patient-Centered Outcomes Research Institute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- State of Louisiana Board of Regents
- Patient-Centered Outcomes Research Institute
Zitieren
APA
Winberg, D., Xuan, D., Tang, T., Marchi, N., & Shi, L. (2025). What is the impact of Inflation Reduction Act negotiated prices for non-insulin diabetes drugs on Louisiana Medicare costs? A forecasting model analysis. Pharmacoeconomics and Policy. https://doi.org/10.1016/j.pharp.2025.09.002
Vancouver
Winberg D, Xuan D, Tang T, Marchi N, Shi L. What is the impact of Inflation Reduction Act negotiated prices for non-insulin diabetes drugs on Louisiana Medicare costs? A forecasting model analysis. Pharmacoeconomics and Policy. 2025. doi:10.1016/j.pharp.2025.09.002
BibTeX
@article{Winberg2025,
author = {Winberg, Debra and Xuan, Dennis and Tang, Tiange and Marchi, Nicolas and Shi, Lizheng},
title = {What is the impact of Inflation Reduction Act negotiated prices for non-insulin diabetes drugs on Louisiana Medicare costs? A forecasting model analysis},
journal = {Pharmacoeconomics and Policy},
year = {2025},
doi = {10.1016/j.pharp.2025.09.002}
}
EUVIMED